January 12, 2023 05:32 PM EST
Pharma
Marketing

Dig­i­tal ther­a­peu­tics 2023: Swing and tri­al part­ner Cu­rav­it kick off fi­bromyal­gia study

Beth Snyder Bulik

Senior Editor

Af­ter the boom-and-bust cy­cling in dig­i­tal ther­a­peu­tics over the past few years, dig­i­tal health providers are look­ing for 2023 to be a sta­bi­liz­ing year. Two …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times